Data / Drug companies / Golden State Medical Supply, Inc.
Golden State Medical Supply, Inc.: 59 products in the FDA NDC directory, labeler code 84677
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Golden State Medical Supply, Inc. (labeler code 84677) lists 59 products in the FDA National Drug Code Directory, covering 17 finished drugs by generic name. By type: 59 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 25, 2026.
The request: Watch Golden State Medical Supply, Inc. (FDA labeler code 84677): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 84677
- Products in commercial distribution
- 59
- Packages
- 84
- Finished drugs by generic name
- 17
- Prescription products
- 59
- Over the counter products
- 0
- Flagged as original packager
- 6 of 6 products that carry the flag
- Started marketing in the last 12 months
- 23
- Earliest marketing start
- December 20, 2006
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 59 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 59 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 20 | 33.9% |
| Tablet | 17 | 28.8% |
| Capsule, extended release | 9 | 15.3% |
| Capsule | 7 | 11.9% |
| Tablet, film coated, extended release | 4 | 6.8% |
| Capsule, delayed release | 2 | 3.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Tofacitinib citrate | 84677-081 | Tablet, film coated, extended release | Generic drugs (ANDA) | June 25, 2026 |
| Pioglitazone hydrochloride | 84677-028 | Tablet | Generic drugs (ANDA) | June 20, 2026 |
| Pioglitazone hydrochloride | 84677-027 | Tablet | Generic drugs (ANDA) | June 20, 2026 |
| Pioglitazone hydrochloride | 84677-026 | Tablet | Generic drugs (ANDA) | June 20, 2026 |
| Dextromethorphan Hydrobromide and Quinidine Sulphate | 84677-067 | Capsule | Generic drugs (ANDA) | June 3, 2026 |
| Tofacitinib | 84677-055 | Tablet, film coated | Generic drugs (ANDA) | June 1, 2026 |
| Tofacitinib | 84677-054 | Tablet, film coated | Generic drugs (ANDA) | June 1, 2026 |
| Sitagliptin and Metformin Hydrochloride | 84677-053 | Tablet, film coated | Generic drugs (ANDA) | April 30, 2026 |
| Sitagliptin and Metformin Hydrochloride | 84677-052 | Tablet, film coated | Generic drugs (ANDA) | April 30, 2026 |
| Valsartan and hydrochlorothiazide | 84677-076 | Tablet, film coated | Generic drugs (ANDA) | April 23, 2026 |
| Valsartan and hydrochlorothiazide | 84677-075 | Tablet, film coated | Generic drugs (ANDA) | April 23, 2026 |
| Valsartan and hydrochlorothiazide | 84677-074 | Tablet, film coated | Generic drugs (ANDA) | April 23, 2026 |
| Valsartan and hydrochlorothiazide | 84677-073 | Tablet, film coated | Generic drugs (ANDA) | April 23, 2026 |
| Valsartan and hydrochlorothiazide | 84677-072 | Tablet, film coated | Generic drugs (ANDA) | April 23, 2026 |
| OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE | 84677-058 | Tablet, film coated | Generic drugs (ANDA) | March 31, 2026 |
| OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE | 84677-057 | Tablet, film coated | Generic drugs (ANDA) | March 31, 2026 |
| OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE | 84677-056 | Tablet, film coated | Generic drugs (ANDA) | March 31, 2026 |
| Dapagliflozin and Metformin Hydrochloride | 84677-022 | Tablet, film coated, extended release | Generic drugs (ANDA) | March 16, 2026 |
| Dapagliflozin and Metformin Hydrochloride | 84677-021 | Tablet, film coated, extended release | Generic drugs (ANDA) | March 16, 2026 |
| Dapagliflozin and Metformin Hydrochloride | 84677-020 | Tablet, film coated, extended release | Generic drugs (ANDA) | March 16, 2026 |
| Sitagliptin | 84677-051 | Tablet, film coated | Generic drugs (ANDA) | January 20, 2026 |
| Sitagliptin | 84677-050 | Tablet, film coated | Generic drugs (ANDA) | January 20, 2026 |
| Sitagliptin | 84677-049 | Tablet, film coated | Generic drugs (ANDA) | January 20, 2026 |
| Lamotrigine | 84677-034 | Tablet | Generic drugs (ANDA) | October 7, 2025 |
| Lamotrigine | 84677-033 | Tablet | Generic drugs (ANDA) | October 7, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.